We stand with people living with cystic fibrosis, their families, care teams, and researchers. This independent lab contributes donated time, research notes, and software experiments, not clinical care or medical advice. Support the wider work through the Cystic Fibrosis Foundation.

Donate to the Cystic Fibrosis Foundation (opens another site)
About this check

The sorting behind these counts was checked against labels made by a council of models; for some classes too few entries could be checked. No person has read the individual rows, and no clinician has read the class definitions.

Trial endpoint atlas

What cystic fibrosis trials register as their main outcomes

A count of the primary (main) outcomes that cystic fibrosis (CF) trials testing a treatment or other intervention entered in ClinicalTrials.gov, grouped by what they measure. Taken from one dated copy of one registry. A trial can register several main outcomes.

Method stage: rule lexicon 0.3.2-draft. The suffix is part of the version id and stays until a person has labeled a sample by hand and checked the class definitions; that check is not yet recorded.

Registry data from ClinicalTrials.gov, an online database; the U.S. National Library of Medicine maintains its website. This lab is independent of the registry; the grouping and counts are the lab's work, not the registry's.

Not shown

For each class named here:

We counted this class but do not show it: on a check against model-made labels, our tagging fell below the lab's accuracy threshold, so the number is not reliable enough to publish.

  • Lung function, not specified
  • Gastrointestinal and pancreatic
  • Liver
  • Other named instrument
  • Patient-reported, instrument not named
  • Microbiology
  • Healthcare use
  • Survival and transplant
  • Feasibility and adherence
  • Physical activity

Not shown does not mean no study registered it: it means our count was not reliable enough to publish.

About 188 of 1072 studies have main outcomes only in classes we do not show. Those classes hold 388 of the 2052 main-outcome entries (18.9%). Some studies may be missing from, or wrongly counted in, this count of studies.

Registry data processed
Dated copy
d164700bb17d
Studies
1072
Main-outcome entries
2052
Sorted by rule
1839 entries, lexicon 0.3.2-draft
Sorted by a model, checked against an exact quote from the record
70 entries
Named no measure
32 entries
Not yet in a class
111 entries
Synthetic marker
none found (this does not prove where the data came from)
Hand check of a sample
not recorded in this data file

Registry records change; the live record on ClinicalTrials.gov is current, this page is not. Open ClinicalTrials.gov (opens another site).

1072studies, the main unit of count
2052main-outcome entries, the unit that is sorted
797studies whose every listed condition names cystic fibrosis
275studies that list cystic fibrosis among other conditions

Studies are the main unit of count: each study is counted once in each class it names. An outcome entry is one main outcome as the trial team wrote it: a measure, a description and a time frame. Each figure states its unit in its caption.

Figures

Choose which figure to show

Figure 1. Studies by class of main outcome and start year

Current registered wording; earlier versions may differ. A measure that appears often is not a better measure. Unit: studies, each counted once in each class it names; a study can name several classes, so the rows can add up to more than the number of studies. Each study is counted once in its start year. Planned start dates are marked as planned. Studies whose registry record gives a start date but no date type are shown with their own mark. Studies with no start date are not in the figure; the note under it gives their count.

  • dot: none in this dated copy
  • ring: 1 to 4 studies, too few to read as a trend
  • filled: 5 or more studies, area shows the count
  • dashed: includes planned starts
  • hatched: year not yet over
  • shaded: planned starts only
  • slash: start date given, type not recorded
Studies by class and start year Rows are the 27 measure classes in the lexicon's order, not sorted by count, grouped by domain. Columns are study start years, 1993 to 2026. Each lit circle is a count of studies, with the number printed beside it. A hatched column labelled year not yet over holds the date the registry processed the data; a shaded column labelled planned only holds start dates after it. Open the table below for every number. 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 year not yet over Lung function and gas exchange FEV1 2 2 3 1 2 2 4 5 5 7 10 8 4 8 5 7 8 16 11 13 10 6 7 3 4 8 1 2 Other spirometry 1 1 2 3 2 4 2 1 1 2 1 3 2 4 3 2 2 1 3 3 1 2 Lung clearance index 3 2 3 1 4 2 2 2 3 2 1 1 Airway resistance, compliance and lung volumes 1 1 1 2 4 1 2 1 Oxygen and carbon dioxide levels 1 1 1 2 1 1 1 2 1 3 1 1 1 1 2 1 1 CFTR function Sweat chloride 1 1 1 1 1 1 4 1 1 2 1 1 Nasal potential difference 1 2 1 1 3 1 1 1 3 1 1 Intestinal current measurement Other CFTR biomarker 1 1 2 3 1 2 1 1 1 1 1 1 Pulmonary exacerbations 1 2 1 1 1 2 6 4 1 2 2 3 3 3 2 2 3 Nutrition and growth 1 2 1 1 4 1 5 1 2 2 1 1 1 6 2 5 3 2 2 1 2 Bone mineral density 1 1 1 1 1 1 1 1 Glucose and cystic fibrosis-related diabetes 2 1 1 2 3 2 1 2 3 1 3 3 1 2 3 4 5 1 3 2 2 2 Sinus and upper airway 1 1 1 1 1 2 1 1 CFQ-R 1 2 1 1 1 1 1 1 1 1 2 3 2 3 1 1 Imaging 1 1 1 2 2 2 1 5 1 1 6 2 1 4 4 2 4 1 Mucus and mucociliary clearance Mucociliary clearance 1 1 2 1 2 1 1 1 1 1 2 1 1 Sputum amount and properties 1 2 1 2 1 1 3 2 3 1 1 1 1 1 Inflammation markers 1 1 2 3 2 8 2 5 2 2 1 2 1 3 3 1 1 1 1 Molecular and oxidative markers Gene expression and methylation 1 1 2 1 1 1 Oxidative stress markers 1 2 2 1 2 1 1 1 1 Safety and tolerability 2 1 1 2 2 6 7 5 11 7 6 10 8 5 13 23 17 16 10 13 8 12 11 12 6 6 Pharmacokinetics 3 1 1 2 9 2 3 6 4 8 5 9 9 7 1 3 5 4 2 3 4 Exercise capacity 1 1 1 2 3 2 1 2 4 5 3 2 4 5 2 2 4 2 2 1 Muscle strength and endurance 1 1 2 1 1 2 1 1 1 Other No measure named 1 6 3 2 1 2 2 1 2 1 2 2 1 1 1 All studies that year, each once 1 0 6 3 2 1 4 5 13 5 16 15 20 36 34 57 49 50 35 48 43 48 65 67 60 56 57 49 55 42 37 38 27 23
Studies by class and start year Rows are the 27 measure classes in the lexicon's order, not sorted by count, grouped by domain. Columns are study start years, 1993 to 2026. Each lit circle is a count of studies, with the number printed under it. A hatched column labelled year not yet over holds the date the registry processed the data; a shaded column labelled planned only holds start dates after it. Open the table below for every number. 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 year not yet over Lung function and gas exchange FEV1 2 2 3 1 2 2 4 5 5 7 10 8 4 8 5 7 8 16 11 13 10 6 7 3 4 8 1 2 Other spirometry 1 1 2 3 2 4 2 1 1 2 1 3 2 4 3 2 2 1 3 3 1 2 Lung clearance index 3 2 3 1 4 2 2 2 3 2 1 1 Airway resistance, compliance and lung volumes 1 1 1 2 4 1 2 1 Oxygen and carbon dioxide levels 1 1 1 2 1 1 1 2 1 3 1 1 1 1 2 1 1 CFTR function Sweat chloride 1 1 1 1 1 1 4 1 1 2 1 1 Nasal potential difference 1 2 1 1 3 1 1 1 3 1 1 Intestinal current measurement Other CFTR biomarker 1 1 2 3 1 2 1 1 1 1 1 1 Pulmonary exacerbations 1 2 1 1 1 2 6 4 1 2 2 3 3 3 2 2 3 Nutrition and growth 1 2 1 1 4 1 5 1 2 2 1 1 1 6 2 5 3 2 2 1 2 Bone mineral density 1 1 1 1 1 1 1 1 Glucose and cystic fibrosis-related diabetes 2 1 1 2 3 2 1 2 3 1 3 3 1 2 3 4 5 1 3 2 2 2 Sinus and upper airway 1 1 1 1 1 2 1 1 CFQ-R 1 2 1 1 1 1 1 1 1 1 2 3 2 3 1 1 Imaging 1 1 1 2 2 2 1 5 1 1 6 2 1 4 4 2 4 1 Mucus and mucociliary clearance Mucociliary clearance 1 1 2 1 2 1 1 1 1 1 2 1 1 Sputum amount and properties 1 2 1 2 1 1 3 2 3 1 1 1 1 1 Inflammation markers 1 1 2 3 2 8 2 5 2 2 1 2 1 3 3 1 1 1 1 Molecular and oxidative markers Gene expression and methylation 1 1 2 1 1 1 Oxidative stress markers 1 2 2 1 2 1 1 1 1 Safety and tolerability 2 1 1 2 2 6 7 5 11 7 6 10 8 5 13 23 17 16 10 13 8 12 11 12 6 6 Pharmacokinetics 3 1 1 2 9 2 3 6 4 8 5 9 9 7 1 3 5 4 2 3 4 Exercise capacity 1 1 1 2 3 2 1 2 4 5 3 2 4 5 2 2 4 2 2 1 Muscle strength and endurance 1 1 2 1 1 2 1 1 1 Other No measure named 1 6 3 2 1 2 2 1 2 1 2 2 1 1 1 All studies that year, each once 1 0 6 3 2 1 4 5 13 5 16 15 20 36 34 57 49 50 35 48 43 48 65 67 60 56 57 49 55 42 37 38 27 23
Studies by class and five-year period of start Rows are the 27 measure classes in the lexicon's order, not sorted by count, grouped by domain. Columns are five-year periods of study start, 1993 to 2026. Each lit circle is a count of studies, with the number printed beside it. A hatched column labelled period not yet over holds the date the registry processed the data; a shaded column labelled planned only holds start dates after it. Open the table below for every number. 1990 –1994 1995 –1999 2000 –2004 2005 –2009 2010 –2014 2015 –2019 2020 –2024 2025 –2029 period not yet over Lung function and gas exchange FEV1 2 10 31 32 58 28 3 Other spirometry 4 11 4 13 11 3 Lung clearance index 3 6 10 5 2 Airway resistance, compliance and lung volumes 1 1 7 4 Oxygen and carbon dioxide levels 5 2 4 5 6 CFTR function Sweat chloride 4 7 3 2 Nasal potential difference 3 6 2 5 Intestinal current measurement Other CFTR biomarker 1 3 4 4 3 1 Pulmonary exacerbations 4 10 12 6 7 Nutrition and growth 4 12 5 8 14 3 Bone mineral density 3 2 3 Glucose and cystic fibrosis-related diabetes 3 6 9 12 15 4 Sinus and upper airway 3 1 4 1 CFQ-R 3 4 4 10 2 Imaging 1 6 10 13 11 Mucus and mucociliary clearance Mucociliary clearance 1 6 4 3 2 Sputum amount and properties 1 5 7 5 2 1 Inflammation markers 4 15 10 3 8 2 Molecular and oxidative markers Gene expression and methylation 2 2 3 Oxidative stress markers 1 2 6 2 1 Safety and tolerability 6 31 36 79 56 12 Pharmacokinetics 7 24 38 15 7 Exercise capacity 2 6 5 18 15 3 Muscle strength and endurance 1 5 4 1 Other No measure named 1 14 6 4 1 2 All studies in that period, each once 1 16 54 196 224 305 221 50
Studies by class and five-year period of start Rows are the 27 measure classes in the lexicon's order, not sorted by count, grouped by domain. Columns are five-year periods of study start, 1993 to 2026. Each lit circle is a count of studies, with the number printed beside it. A hatched column labelled period not yet over holds the date the registry processed the data; a shaded column labelled planned only holds start dates after it. Open the table below for every number. 1990 –1994 1995 –1999 2000 –2004 2005 –2009 2010 –2014 2015 –2019 2020 –2024 2025 –2029 period not yet over Lung function and gas exchange FEV1 2 10 31 32 58 28 3 Other spirometry 4 11 4 13 11 3 Lung clearance index 3 6 10 5 2 Airway resistance, compliance and lung volumes 1 1 7 4 Oxygen and carbon dioxide levels 5 2 4 5 6 CFTR function Sweat chloride 4 7 3 2 Nasal potential difference 3 6 2 5 Intestinal current measurement Other CFTR biomarker 1 3 4 4 3 1 Pulmonary exacerbations 4 10 12 6 7 Nutrition and growth 4 12 5 8 14 3 Bone mineral density 3 2 3 Glucose and cystic fibrosis-related diabetes 3 6 9 12 15 4 Sinus and upper airway 3 1 4 1 CFQ-R 3 4 4 10 2 Imaging 1 6 10 13 11 Mucus and mucociliary clearance Mucociliary clearance 1 6 4 3 2 Sputum amount and properties 1 5 7 5 2 1 Inflammation markers 4 15 10 3 8 2 Molecular and oxidative markers Gene expression and methylation 2 2 3 Oxidative stress markers 1 2 6 2 1 Safety and tolerability 6 31 36 79 56 12 Pharmacokinetics 7 24 38 15 7 Exercise capacity 2 6 5 18 15 3 Muscle strength and endurance 1 5 4 1 Other No measure named 1 14 6 4 1 2 All studies in that period, each once 1 16 54 196 224 305 221 50
Figure 1 by five-year period, as a table: 27 class rows, and a total row
Figure 1 as a table: studies per class and five-year period
Class1990–19941995–19992000–20042005–20092010–20142015–20192020–20242025–2029 (period not yet over)
FEV10FEV1, 1995–1999: 2 (2 type not recorded)FEV1, 2000–2004: 10 (8 type not recorded)FEV1, 2005–2009: 31 (28 type not recorded)FEV1, 2010–2014: 32 (21 type not recorded)FEV1, 2015–2019: 58 (1 planned, 10 type not recorded)FEV1, 2020–2024: 28 (2 planned)FEV1, 2025–2029: 3 (1 planned)
Other spirometry00Other spirometry, 2000–2004: 4 (3 type not recorded)Other spirometry, 2005–2009: 11 (10 type not recorded)Other spirometry, 2010–2014: 4 (3 type not recorded)Other spirometry, 2015–2019: 13 (1 type not recorded)Other spirometry, 2020–2024: 11Other spirometry, 2025–2029: 3 (1 planned)
Lung clearance index000Lung clearance index, 2005–2009: 3 (2 type not recorded)Lung clearance index, 2010–2014: 6 (4 type not recorded)Lung clearance index, 2015–2019: 10 (2 type not recorded)Lung clearance index, 2020–2024: 5 (1 planned)Lung clearance index, 2025–2029: 2 (1 planned)
Airway resistance, compliance and lung volumes000Airway resistance, compliance and lung volumes, 2005–2009: 1 (1 type not recorded)Airway resistance, compliance and lung volumes, 2010–2014: 1Airway resistance, compliance and lung volumes, 2015–2019: 7 (1 planned)Airway resistance, compliance and lung volumes, 2020–2024: 40
Oxygen and carbon dioxide levels00Oxygen and carbon dioxide levels, 2000–2004: 5 (5 type not recorded)Oxygen and carbon dioxide levels, 2005–2009: 2 (2 type not recorded)Oxygen and carbon dioxide levels, 2010–2014: 4 (3 type not recorded)Oxygen and carbon dioxide levels, 2015–2019: 5 (1 type not recorded)Oxygen and carbon dioxide levels, 2020–2024: 60
Sweat chloride0000Sweat chloride, 2010–2014: 4 (3 type not recorded)Sweat chloride, 2015–2019: 7Sweat chloride, 2020–2024: 3Sweat chloride, 2025–2029: 2 (2 planned)
Nasal potential difference00Nasal potential difference, 2000–2004: 3 (3 type not recorded)Nasal potential difference, 2005–2009: 6 (5 type not recorded)Nasal potential difference, 2010–2014: 2 (1 type not recorded)Nasal potential difference, 2015–2019: 5 (2 type not recorded)00
Intestinal current measurement00000000
Other CFTR biomarker00Other CFTR biomarker, 2000–2004: 1 (1 type not recorded)Other CFTR biomarker, 2005–2009: 3 (2 type not recorded)Other CFTR biomarker, 2010–2014: 4 (3 type not recorded)Other CFTR biomarker, 2015–2019: 4 (1 type not recorded)Other CFTR biomarker, 2020–2024: 3 (1 planned)Other CFTR biomarker, 2025–2029: 1
Pulmonary exacerbations00Pulmonary exacerbations, 2000–2004: 4 (4 type not recorded)Pulmonary exacerbations, 2005–2009: 10 (9 type not recorded)Pulmonary exacerbations, 2010–2014: 12 (11 type not recorded)Pulmonary exacerbations, 2015–2019: 6 (1 type not recorded)Pulmonary exacerbations, 2020–2024: 7 (2 planned)0
Nutrition and growth00Nutrition and growth, 2000–2004: 4 (4 type not recorded)Nutrition and growth, 2005–2009: 12 (11 type not recorded)Nutrition and growth, 2010–2014: 5 (3 type not recorded)Nutrition and growth, 2015–2019: 8Nutrition and growth, 2020–2024: 14 (2 planned)Nutrition and growth, 2025–2029: 3 (2 planned)
Bone mineral density00Bone mineral density, 2000–2004: 3 (3 type not recorded)0Bone mineral density, 2010–2014: 2 (1 type not recorded)0Bone mineral density, 2020–2024: 30
Glucose and cystic fibrosis-related diabetes00Glucose and cystic fibrosis-related diabetes, 2000–2004: 3 (3 type not recorded)Glucose and cystic fibrosis-related diabetes, 2005–2009: 6 (6 type not recorded)Glucose and cystic fibrosis-related diabetes, 2010–2014: 9 (1 planned, 7 type not recorded)Glucose and cystic fibrosis-related diabetes, 2015–2019: 12 (4 type not recorded)Glucose and cystic fibrosis-related diabetes, 2020–2024: 15Glucose and cystic fibrosis-related diabetes, 2025–2029: 4 (2 planned)
Sinus and upper airway000Sinus and upper airway, 2005–2009: 3 (3 type not recorded)Sinus and upper airway, 2010–2014: 1 (1 type not recorded)Sinus and upper airway, 2015–2019: 40Sinus and upper airway, 2025–2029: 1
CFQ-R000CFQ-R, 2005–2009: 3 (3 type not recorded)CFQ-R, 2010–2014: 4 (3 type not recorded)CFQ-R, 2015–2019: 4 (1 type not recorded)CFQ-R, 2020–2024: 10 (2 planned)CFQ-R, 2025–2029: 2 (1 planned)
Imaging00Imaging, 2000–2004: 1 (1 type not recorded)Imaging, 2005–2009: 6 (5 type not recorded)Imaging, 2010–2014: 10 (7 type not recorded)Imaging, 2015–2019: 13 (1 planned, 1 type not recorded)Imaging, 2020–2024: 110
Mucociliary clearance00Mucociliary clearance, 2000–2004: 1 (1 type not recorded)Mucociliary clearance, 2005–2009: 6 (6 type not recorded)Mucociliary clearance, 2010–2014: 4 (4 type not recorded)Mucociliary clearance, 2015–2019: 3 (1 type not recorded)Mucociliary clearance, 2020–2024: 20
Sputum amount and properties00Sputum amount and properties, 2000–2004: 1 (1 type not recorded)Sputum amount and properties, 2005–2009: 5 (5 type not recorded)Sputum amount and properties, 2010–2014: 7 (7 type not recorded)Sputum amount and properties, 2015–2019: 5 (1 type not recorded)Sputum amount and properties, 2020–2024: 2Sputum amount and properties, 2025–2029: 1
Inflammation markers00Inflammation markers, 2000–2004: 4 (4 type not recorded)Inflammation markers, 2005–2009: 15 (12 type not recorded)Inflammation markers, 2010–2014: 10 (9 type not recorded)Inflammation markers, 2015–2019: 3 (1 type not recorded)Inflammation markers, 2020–2024: 8 (1 planned)Inflammation markers, 2025–2029: 2 (2 planned)
Gene expression and methylation0000Gene expression and methylation, 2010–2014: 2 (1 type not recorded)Gene expression and methylation, 2015–2019: 2Gene expression and methylation, 2020–2024: 30
Oxidative stress markers00Oxidative stress markers, 2000–2004: 1 (1 type not recorded)Oxidative stress markers, 2005–2009: 2 (2 type not recorded)Oxidative stress markers, 2010–2014: 6 (5 type not recorded)0Oxidative stress markers, 2020–2024: 2Oxidative stress markers, 2025–2029: 1 (1 planned)
Safety and tolerability00Safety and tolerability, 2000–2004: 6 (5 type not recorded)Safety and tolerability, 2005–2009: 31 (26 type not recorded)Safety and tolerability, 2010–2014: 36 (31 type not recorded)Safety and tolerability, 2015–2019: 79 (17 type not recorded)Safety and tolerability, 2020–2024: 56 (3 planned)Safety and tolerability, 2025–2029: 12 (3 planned)
Pharmacokinetics000Pharmacokinetics, 2005–2009: 7 (7 type not recorded)Pharmacokinetics, 2010–2014: 24 (1 planned, 22 type not recorded)Pharmacokinetics, 2015–2019: 38 (1 planned, 10 type not recorded)Pharmacokinetics, 2020–2024: 15Pharmacokinetics, 2025–2029: 7 (3 planned)
Exercise capacity00Exercise capacity, 2000–2004: 2 (2 type not recorded)Exercise capacity, 2005–2009: 6 (6 type not recorded)Exercise capacity, 2010–2014: 5 (4 type not recorded)Exercise capacity, 2015–2019: 18 (4 type not recorded)Exercise capacity, 2020–2024: 15 (1 planned)Exercise capacity, 2025–2029: 3 (1 planned)
Muscle strength and endurance000Muscle strength and endurance, 2005–2009: 1 (1 type not recorded)0Muscle strength and endurance, 2015–2019: 5Muscle strength and endurance, 2020–2024: 4 (1 planned)Muscle strength and endurance, 2025–2029: 1
Other00000000
No measure namedNo measure named, 1990–1994: 1 (1 type not recorded)No measure named, 1995–1999: 14 (14 type not recorded)No measure named, 2000–2004: 6 (4 type not recorded)No measure named, 2005–2009: 4 (2 planned, 2 type not recorded)No measure named, 2010–2014: 1 (1 type not recorded)No measure named, 2015–2019: 200
All studies in that period, each once1165419622430522150
Figure 1 as a table: 27 class rows, and a total row
Figure 1 as a table: studies per class and start year
Class1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026 (year not yet over)
FEV1000000FEV1, 1999: 2 (2 type not recorded)FEV1, 2000: 2 (1 type not recorded)FEV1, 2001: 3 (3 type not recorded)FEV1, 2002: 1FEV1, 2003: 2 (2 type not recorded)FEV1, 2004: 2 (2 type not recorded)FEV1, 2005: 4 (4 type not recorded)FEV1, 2006: 5 (5 type not recorded)FEV1, 2007: 5 (5 type not recorded)FEV1, 2008: 7 (6 type not recorded)FEV1, 2009: 10 (8 type not recorded)FEV1, 2010: 8 (7 type not recorded)FEV1, 2011: 4 (3 type not recorded)FEV1, 2012: 8 (6 type not recorded)FEV1, 2013: 5 (3 type not recorded)FEV1, 2014: 7 (2 type not recorded)FEV1, 2015: 8 (5 type not recorded)FEV1, 2016: 16 (5 type not recorded)FEV1, 2017: 11FEV1, 2018: 13 (1 planned)FEV1, 2019: 10FEV1, 2020: 6FEV1, 2021: 7 (1 planned)FEV1, 2022: 3 (1 planned)FEV1, 2023: 4FEV1, 2024: 8FEV1, 2025: 1FEV1, 2026: 2 (1 planned)
Other spirometry0000000Other spirometry, 2000: 1 (1 type not recorded)Other spirometry, 2001: 1 (1 type not recorded)Other spirometry, 2002: 2 (1 type not recorded)00Other spirometry, 2005: 3 (3 type not recorded)Other spirometry, 2006: 2 (2 type not recorded)0Other spirometry, 2008: 4 (3 type not recorded)Other spirometry, 2009: 2 (2 type not recorded)Other spirometry, 2010: 10Other spirometry, 2012: 1 (1 type not recorded)Other spirometry, 2013: 2 (2 type not recorded)0Other spirometry, 2015: 1Other spirometry, 2016: 3 (1 type not recorded)Other spirometry, 2017: 2Other spirometry, 2018: 4Other spirometry, 2019: 3Other spirometry, 2020: 2Other spirometry, 2021: 2Other spirometry, 2022: 1Other spirometry, 2023: 3Other spirometry, 2024: 3Other spirometry, 2025: 1Other spirometry, 2026: 2 (1 planned)
Lung clearance index000000000000000Lung clearance index, 2008: 3 (2 type not recorded)00Lung clearance index, 2011: 2 (2 type not recorded)Lung clearance index, 2012: 3 (2 type not recorded)0Lung clearance index, 2014: 1Lung clearance index, 2015: 4 (1 type not recorded)Lung clearance index, 2016: 2 (1 type not recorded)Lung clearance index, 2017: 2Lung clearance index, 2018: 20Lung clearance index, 2020: 30Lung clearance index, 2022: 2 (1 planned)00Lung clearance index, 2025: 1Lung clearance index, 2026: 1 (1 planned)
Airway resistance, compliance and lung volumes000000000000000Airway resistance, compliance and lung volumes, 2008: 1 (1 type not recorded)00000Airway resistance, compliance and lung volumes, 2014: 10Airway resistance, compliance and lung volumes, 2016: 10Airway resistance, compliance and lung volumes, 2018: 2Airway resistance, compliance and lung volumes, 2019: 4 (1 planned)Airway resistance, compliance and lung volumes, 2020: 10Airway resistance, compliance and lung volumes, 2022: 20Airway resistance, compliance and lung volumes, 2024: 100
Oxygen and carbon dioxide levels00000000Oxygen and carbon dioxide levels, 2001: 1 (1 type not recorded)Oxygen and carbon dioxide levels, 2002: 1 (1 type not recorded)Oxygen and carbon dioxide levels, 2003: 1 (1 type not recorded)Oxygen and carbon dioxide levels, 2004: 2 (2 type not recorded)Oxygen and carbon dioxide levels, 2005: 1 (1 type not recorded)Oxygen and carbon dioxide levels, 2006: 1 (1 type not recorded)000Oxygen and carbon dioxide levels, 2010: 1 (1 type not recorded)0Oxygen and carbon dioxide levels, 2012: 2 (1 type not recorded)0Oxygen and carbon dioxide levels, 2014: 1 (1 type not recorded)0Oxygen and carbon dioxide levels, 2016: 3 (1 type not recorded)Oxygen and carbon dioxide levels, 2017: 1Oxygen and carbon dioxide levels, 2018: 10Oxygen and carbon dioxide levels, 2020: 1Oxygen and carbon dioxide levels, 2021: 1Oxygen and carbon dioxide levels, 2022: 2Oxygen and carbon dioxide levels, 2023: 1Oxygen and carbon dioxide levels, 2024: 100
Sweat chloride00000000000000000Sweat chloride, 2010: 1 (1 type not recorded)0Sweat chloride, 2012: 1 (1 type not recorded)Sweat chloride, 2013: 1 (1 type not recorded)Sweat chloride, 2014: 10Sweat chloride, 2016: 1Sweat chloride, 2017: 1Sweat chloride, 2018: 4Sweat chloride, 2019: 10Sweat chloride, 2021: 100Sweat chloride, 2024: 2Sweat chloride, 2025: 1 (1 planned)Sweat chloride, 2026: 1 (1 planned)
Nasal potential difference00000000Nasal potential difference, 2001: 1 (1 type not recorded)0Nasal potential difference, 2003: 2 (2 type not recorded)0Nasal potential difference, 2005: 1 (1 type not recorded)Nasal potential difference, 2006: 1 (1 type not recorded)Nasal potential difference, 2007: 3 (2 type not recorded)Nasal potential difference, 2008: 1 (1 type not recorded)0Nasal potential difference, 2010: 1 (1 type not recorded)Nasal potential difference, 2011: 1000Nasal potential difference, 2015: 3 (2 type not recorded)0Nasal potential difference, 2017: 1Nasal potential difference, 2018: 100000000
Intestinal current measurement0000000000000000000000000000000000
Other CFTR biomarker0000000000Other CFTR biomarker, 2003: 1 (1 type not recorded)0Other CFTR biomarker, 2005: 1000Other CFTR biomarker, 2009: 2 (2 type not recorded)0Other CFTR biomarker, 2011: 3 (2 type not recorded)Other CFTR biomarker, 2012: 1 (1 type not recorded)00Other CFTR biomarker, 2015: 2 (1 type not recorded)0Other CFTR biomarker, 2017: 1Other CFTR biomarker, 2018: 10Other CFTR biomarker, 2020: 1 (1 planned)Other CFTR biomarker, 2021: 1Other CFTR biomarker, 2022: 100Other CFTR biomarker, 2025: 10
Pulmonary exacerbations00000000Pulmonary exacerbations, 2001: 1 (1 type not recorded)0Pulmonary exacerbations, 2003: 2 (2 type not recorded)Pulmonary exacerbations, 2004: 1 (1 type not recorded)Pulmonary exacerbations, 2005: 1 (1 type not recorded)0Pulmonary exacerbations, 2007: 1 (1 type not recorded)Pulmonary exacerbations, 2008: 2 (2 type not recorded)Pulmonary exacerbations, 2009: 6 (5 type not recorded)Pulmonary exacerbations, 2010: 4 (3 type not recorded)Pulmonary exacerbations, 2011: 1 (1 type not recorded)Pulmonary exacerbations, 2012: 2 (2 type not recorded)Pulmonary exacerbations, 2013: 2 (2 type not recorded)Pulmonary exacerbations, 2014: 3 (3 type not recorded)0Pulmonary exacerbations, 2016: 3 (1 type not recorded)Pulmonary exacerbations, 2017: 30000Pulmonary exacerbations, 2022: 2 (1 planned)Pulmonary exacerbations, 2023: 2 (1 planned)Pulmonary exacerbations, 2024: 300
Nutrition and growth00000000Nutrition and growth, 2001: 1 (1 type not recorded)0Nutrition and growth, 2003: 2 (2 type not recorded)Nutrition and growth, 2004: 1 (1 type not recorded)Nutrition and growth, 2005: 1 (1 type not recorded)Nutrition and growth, 2006: 4 (3 type not recorded)Nutrition and growth, 2007: 1 (1 type not recorded)Nutrition and growth, 2008: 5 (5 type not recorded)Nutrition and growth, 2009: 1 (1 type not recorded)Nutrition and growth, 2010: 2 (1 type not recorded)Nutrition and growth, 2011: 2 (1 type not recorded)Nutrition and growth, 2012: 1 (1 type not recorded)000Nutrition and growth, 2016: 1Nutrition and growth, 2017: 1Nutrition and growth, 2018: 60Nutrition and growth, 2020: 2Nutrition and growth, 2021: 5Nutrition and growth, 2022: 3 (2 planned)Nutrition and growth, 2023: 2Nutrition and growth, 2024: 2Nutrition and growth, 2025: 1Nutrition and growth, 2026: 2 (2 planned)
Bone mineral density00000000Bone mineral density, 2001: 1 (1 type not recorded)Bone mineral density, 2002: 1 (1 type not recorded)Bone mineral density, 2003: 1 (1 type not recorded)00000000Bone mineral density, 2012: 1Bone mineral density, 2013: 1 (1 type not recorded)000000Bone mineral density, 2020: 1Bone mineral density, 2021: 10Bone mineral density, 2023: 1000
Glucose and cystic fibrosis-related diabetes00000000Glucose and cystic fibrosis-related diabetes, 2001: 2 (2 type not recorded)0Glucose and cystic fibrosis-related diabetes, 2003: 1 (1 type not recorded)0Glucose and cystic fibrosis-related diabetes, 2005: 1 (1 type not recorded)00Glucose and cystic fibrosis-related diabetes, 2008: 2 (2 type not recorded)Glucose and cystic fibrosis-related diabetes, 2009: 3 (3 type not recorded)Glucose and cystic fibrosis-related diabetes, 2010: 2 (2 type not recorded)Glucose and cystic fibrosis-related diabetes, 2011: 1 (1 planned)Glucose and cystic fibrosis-related diabetes, 2012: 2 (1 type not recorded)Glucose and cystic fibrosis-related diabetes, 2013: 3 (3 type not recorded)Glucose and cystic fibrosis-related diabetes, 2014: 1 (1 type not recorded)Glucose and cystic fibrosis-related diabetes, 2015: 3 (2 type not recorded)Glucose and cystic fibrosis-related diabetes, 2016: 3 (2 type not recorded)Glucose and cystic fibrosis-related diabetes, 2017: 1Glucose and cystic fibrosis-related diabetes, 2018: 2Glucose and cystic fibrosis-related diabetes, 2019: 3Glucose and cystic fibrosis-related diabetes, 2020: 4Glucose and cystic fibrosis-related diabetes, 2021: 5Glucose and cystic fibrosis-related diabetes, 2022: 1Glucose and cystic fibrosis-related diabetes, 2023: 3Glucose and cystic fibrosis-related diabetes, 2024: 2Glucose and cystic fibrosis-related diabetes, 2025: 2Glucose and cystic fibrosis-related diabetes, 2026: 2 (2 planned)
Sinus and upper airway000000000000Sinus and upper airway, 2005: 1 (1 type not recorded)Sinus and upper airway, 2006: 1 (1 type not recorded)Sinus and upper airway, 2007: 1 (1 type not recorded)00Sinus and upper airway, 2010: 1 (1 type not recorded)0000Sinus and upper airway, 2015: 10Sinus and upper airway, 2017: 20Sinus and upper airway, 2019: 100000Sinus and upper airway, 2025: 10
CFQ-R000000000000CFQ-R, 2005: 1 (1 type not recorded)00CFQ-R, 2008: 2 (2 type not recorded)0CFQ-R, 2010: 1 (1 type not recorded)0CFQ-R, 2012: 1 (1 type not recorded)CFQ-R, 2013: 1 (1 type not recorded)CFQ-R, 2014: 1CFQ-R, 2015: 1 (1 type not recorded)CFQ-R, 2016: 1CFQ-R, 2017: 10CFQ-R, 2019: 1CFQ-R, 2020: 20CFQ-R, 2022: 3 (1 planned)CFQ-R, 2023: 2 (1 planned)CFQ-R, 2024: 3CFQ-R, 2025: 1CFQ-R, 2026: 1 (1 planned)
Imaging00000000Imaging, 2001: 1 (1 type not recorded)000Imaging, 2005: 1 (1 type not recorded)Imaging, 2006: 1 (1 type not recorded)0Imaging, 2008: 2 (2 type not recorded)Imaging, 2009: 2 (1 type not recorded)Imaging, 2010: 2 (2 type not recorded)Imaging, 2011: 1Imaging, 2012: 5 (3 type not recorded)Imaging, 2013: 1 (1 type not recorded)Imaging, 2014: 1 (1 type not recorded)Imaging, 2015: 6 (1 type not recorded)Imaging, 2016: 2Imaging, 2017: 1 (1 planned)Imaging, 2018: 40Imaging, 2020: 4Imaging, 2021: 2Imaging, 2022: 40Imaging, 2024: 100
Mucociliary clearance000000000Mucociliary clearance, 2002: 1 (1 type not recorded)00Mucociliary clearance, 2005: 1 (1 type not recorded)0Mucociliary clearance, 2007: 2 (2 type not recorded)Mucociliary clearance, 2008: 1 (1 type not recorded)Mucociliary clearance, 2009: 2 (2 type not recorded)Mucociliary clearance, 2010: 1 (1 type not recorded)Mucociliary clearance, 2011: 1 (1 type not recorded)Mucociliary clearance, 2012: 1 (1 type not recorded)0Mucociliary clearance, 2014: 1 (1 type not recorded)0Mucociliary clearance, 2016: 1 (1 type not recorded)Mucociliary clearance, 2017: 20000Mucociliary clearance, 2022: 1Mucociliary clearance, 2023: 1000
Sputum amount and properties0000000000Sputum amount and properties, 2003: 1 (1 type not recorded)00Sputum amount and properties, 2006: 2 (2 type not recorded)Sputum amount and properties, 2007: 1 (1 type not recorded)Sputum amount and properties, 2008: 2 (2 type not recorded)0Sputum amount and properties, 2010: 1 (1 type not recorded)0Sputum amount and properties, 2012: 1 (1 type not recorded)Sputum amount and properties, 2013: 3 (3 type not recorded)Sputum amount and properties, 2014: 2 (2 type not recorded)0Sputum amount and properties, 2016: 3 (1 type not recorded)Sputum amount and properties, 2017: 10Sputum amount and properties, 2019: 1Sputum amount and properties, 2020: 100Sputum amount and properties, 2023: 10Sputum amount and properties, 2025: 10
Inflammation markers000000000Inflammation markers, 2002: 1 (1 type not recorded)Inflammation markers, 2003: 1 (1 type not recorded)Inflammation markers, 2004: 2 (2 type not recorded)0Inflammation markers, 2006: 3 (3 type not recorded)Inflammation markers, 2007: 2 (2 type not recorded)Inflammation markers, 2008: 8 (6 type not recorded)Inflammation markers, 2009: 2 (1 type not recorded)Inflammation markers, 2010: 5 (5 type not recorded)Inflammation markers, 2011: 2 (2 type not recorded)Inflammation markers, 2012: 2 (2 type not recorded)Inflammation markers, 2013: 10Inflammation markers, 2015: 2 (1 type not recorded)00Inflammation markers, 2018: 10Inflammation markers, 2020: 3Inflammation markers, 2021: 3Inflammation markers, 2022: 1 (1 planned)Inflammation markers, 2023: 10Inflammation markers, 2025: 1 (1 planned)Inflammation markers, 2026: 1 (1 planned)
Gene expression and methylation00000000000000000Gene expression and methylation, 2010: 100Gene expression and methylation, 2013: 1 (1 type not recorded)00Gene expression and methylation, 2016: 2000Gene expression and methylation, 2020: 1Gene expression and methylation, 2021: 1Gene expression and methylation, 2022: 10000
Oxidative stress markers00000000000Oxidative stress markers, 2004: 1 (1 type not recorded)00Oxidative stress markers, 2007: 2 (2 type not recorded)00Oxidative stress markers, 2010: 2 (2 type not recorded)Oxidative stress markers, 2011: 1 (1 type not recorded)0Oxidative stress markers, 2013: 2 (2 type not recorded)Oxidative stress markers, 2014: 100000000Oxidative stress markers, 2023: 1Oxidative stress markers, 2024: 1Oxidative stress markers, 2025: 1 (1 planned)0
Safety and tolerability00000000Safety and tolerability, 2001: 2 (2 type not recorded)Safety and tolerability, 2002: 1 (1 type not recorded)Safety and tolerability, 2003: 1 (1 type not recorded)Safety and tolerability, 2004: 2 (1 type not recorded)Safety and tolerability, 2005: 2 (2 type not recorded)Safety and tolerability, 2006: 6 (6 type not recorded)Safety and tolerability, 2007: 7 (6 type not recorded)Safety and tolerability, 2008: 5 (4 type not recorded)Safety and tolerability, 2009: 11 (8 type not recorded)Safety and tolerability, 2010: 7 (6 type not recorded)Safety and tolerability, 2011: 6 (6 type not recorded)Safety and tolerability, 2012: 10 (7 type not recorded)Safety and tolerability, 2013: 8 (8 type not recorded)Safety and tolerability, 2014: 5 (4 type not recorded)Safety and tolerability, 2015: 13 (8 type not recorded)Safety and tolerability, 2016: 23 (8 type not recorded)Safety and tolerability, 2017: 17 (1 type not recorded)Safety and tolerability, 2018: 16Safety and tolerability, 2019: 10Safety and tolerability, 2020: 13 (1 planned)Safety and tolerability, 2021: 8 (1 planned)Safety and tolerability, 2022: 12 (1 planned)Safety and tolerability, 2023: 11Safety and tolerability, 2024: 12Safety and tolerability, 2025: 6 (1 planned)Safety and tolerability, 2026: 6 (2 planned)
Pharmacokinetics0000000000000Pharmacokinetics, 2006: 3 (3 type not recorded)Pharmacokinetics, 2007: 1 (1 type not recorded)Pharmacokinetics, 2008: 1 (1 type not recorded)Pharmacokinetics, 2009: 2 (2 type not recorded)Pharmacokinetics, 2010: 9 (9 type not recorded)Pharmacokinetics, 2011: 2 (2 type not recorded)Pharmacokinetics, 2012: 3 (1 planned, 2 type not recorded)Pharmacokinetics, 2013: 6 (6 type not recorded)Pharmacokinetics, 2014: 4 (3 type not recorded)Pharmacokinetics, 2015: 8 (8 type not recorded)Pharmacokinetics, 2016: 5 (2 type not recorded)Pharmacokinetics, 2017: 9Pharmacokinetics, 2018: 9Pharmacokinetics, 2019: 7 (1 planned)Pharmacokinetics, 2020: 1Pharmacokinetics, 2021: 3Pharmacokinetics, 2022: 5Pharmacokinetics, 2023: 4Pharmacokinetics, 2024: 2Pharmacokinetics, 2025: 3Pharmacokinetics, 2026: 4 (3 planned)
Exercise capacity0000000Exercise capacity, 2000: 1 (1 type not recorded)000Exercise capacity, 2004: 1 (1 type not recorded)0Exercise capacity, 2006: 1 (1 type not recorded)Exercise capacity, 2007: 2 (2 type not recorded)Exercise capacity, 2008: 3 (3 type not recorded)00Exercise capacity, 2011: 2 (2 type not recorded)Exercise capacity, 2012: 1 (1 type not recorded)0Exercise capacity, 2014: 2 (1 type not recorded)Exercise capacity, 2015: 4 (3 type not recorded)Exercise capacity, 2016: 5 (1 type not recorded)Exercise capacity, 2017: 3Exercise capacity, 2018: 2Exercise capacity, 2019: 4Exercise capacity, 2020: 5 (1 planned)Exercise capacity, 2021: 2Exercise capacity, 2022: 2Exercise capacity, 2023: 4Exercise capacity, 2024: 2Exercise capacity, 2025: 2Exercise capacity, 2026: 1 (1 planned)
Muscle strength and endurance000000000000Muscle strength and endurance, 2005: 1 (1 type not recorded)0000000000Muscle strength and endurance, 2016: 1Muscle strength and endurance, 2017: 2Muscle strength and endurance, 2018: 1Muscle strength and endurance, 2019: 1Muscle strength and endurance, 2020: 2 (1 planned)Muscle strength and endurance, 2021: 100Muscle strength and endurance, 2024: 1Muscle strength and endurance, 2025: 10
Other0000000000000000000000000000000000
No measure namedNo measure named, 1993: 1 (1 type not recorded)0No measure named, 1995: 6 (6 type not recorded)No measure named, 1996: 3 (3 type not recorded)No measure named, 1997: 2 (2 type not recorded)No measure named, 1998: 1 (1 type not recorded)No measure named, 1999: 2 (2 type not recorded)No measure named, 2000: 2 (1 type not recorded)No measure named, 2001: 1 (1 type not recorded)0No measure named, 2003: 2 (1 type not recorded)No measure named, 2004: 1 (1 type not recorded)0No measure named, 2006: 2 (2 planned)00No measure named, 2009: 2 (2 type not recorded)0No measure named, 2011: 1 (1 type not recorded)0000No measure named, 2016: 100No measure named, 2019: 10000000
All studies that year, each once10632145135161520363457495035484348656760565749554237382723

Studies with no start date are not in the figure: 5.

Figure 2. Studies by class of main outcome and trial phase

Current registered wording; earlier versions may differ. A measure that appears often is not a better measure. Unit: studies, each counted once in each class it names; a study can name several classes, so the rows can add up to more than the number of studies. A total across classes is not shown, because a study in several classes would be counted more than once. NA is shown as the registry wrote it; this page does not treat it as missing.

  • dot: none in this dated copy
  • ring: 1 to 4 studies, too few to read as a trend
  • filled: 5 or more studies, area shows the count
Studies by class and trial phase Rows are the 27 measure classes in the lexicon's order, grouped by domain. Columns are trial phases as the registry records them. Each lit circle is a count of studies, with the number printed beside it. Open the table below for every number. Early phase 1 Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 NA Lung function and gas exchange FEV1 1 6 9 48 1 42 14 43 Other spirometry 1 10 3 6 4 3 19 Lung clearance index 2 3 7 3 11 Airway resistance, compliance and lung volumes 2 11 Oxygen and carbon dioxide levels 4 4 2 1 1 1 9 CFTR function Sweat chloride 1 8 7 Nasal potential difference 1 3 9 1 2 Intestinal current measurement Other CFTR biomarker 4 12 Pulmonary exacerbations 1 2 1 10 8 6 12 Nutrition and growth 2 2 3 2 5 2 30 Bone mineral density 1 5 2 Glucose and cystic fibrosis-related diabetes 2 1 3 3 7 2 31 Sinus and upper airway 1 1 4 3 CFQ-R 2 4 1 16 Imaging 5 3 1 8 1 2 5 16 Mucus and mucociliary clearance Mucociliary clearance 1 6 4 1 4 Sputum amount and properties 3 1 2 15 Inflammation markers 3 5 8 4 3 19 Molecular and oxidative markers Gene expression and methylation 1 6 Oxidative stress markers 3 1 8 Safety and tolerability 2 60 30 50 48 7 23 Pharmacokinetics 41 8 6 1 11 12 12 Exercise capacity 1 1 3 2 3 39 Muscle strength and endurance 11 Other No measure named 8 5 2 3 1 13
Studies by class and trial phase Rows are the 27 measure classes in the lexicon's order, grouped by domain. Columns are trial phases as the registry records them. Each lit circle is a count of studies, with the number printed beside it. Open the table below for every number. Early phase 1 Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 NA Lung function and gas exchange FEV1 1 6 9 48 1 42 14 43 Other spirometry 1 10 3 6 4 3 19 Lung clearance index 2 3 7 3 11 Airway resistance, compliance and lung volumes 2 11 Oxygen and carbon dioxide levels 4 4 2 1 1 1 9 CFTR function Sweat chloride 1 8 7 Nasal potential difference 1 3 9 1 2 Intestinal current measurement Other CFTR biomarker 4 12 Pulmonary exacerbations 1 2 1 10 8 6 12 Nutrition and growth 2 2 3 2 5 2 30 Bone mineral density 1 5 2 Glucose and cystic fibrosis-related diabetes 2 1 3 3 7 2 31 Sinus and upper airway 1 1 4 3 CFQ-R 2 4 1 16 Imaging 5 3 1 8 1 2 5 16 Mucus and mucociliary clearance Mucociliary clearance 1 6 4 1 4 Sputum amount and properties 3 1 2 15 Inflammation markers 3 5 8 4 3 19 Molecular and oxidative markers Gene expression and methylation 1 6 Oxidative stress markers 3 1 8 Safety and tolerability 2 60 30 50 48 7 23 Pharmacokinetics 41 8 6 1 11 12 12 Exercise capacity 1 1 3 2 3 39 Muscle strength and endurance 11 Other No measure named 8 5 2 3 1 13
Studies by class and trial phase Rows are the 27 measure classes in the lexicon's order, grouped by domain. Columns are trial phases as the registry records them. Each lit circle is a count of studies, with the number printed beside it. Open the table below for every number. Early phase 1 Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 NA Lung function and gas exchange FEV1 1 6 9 48 1 42 14 43 Other spirometry 1 10 3 6 4 3 19 Lung clearance index 2 3 7 3 11 Airway resistance, compliance and lung volumes 2 11 Oxygen and carbon dioxide levels 4 4 2 1 1 1 9 CFTR function Sweat chloride 1 8 7 Nasal potential difference 1 3 9 1 2 Intestinal current measurement Other CFTR biomarker 4 12 Pulmonary exacerbations 1 2 1 10 8 6 12 Nutrition and growth 2 2 3 2 5 2 30 Bone mineral density 1 5 2 Glucose and cystic fibrosis-related diabetes 2 1 3 3 7 2 31 Sinus and upper airway 1 1 4 3 CFQ-R 2 4 1 16 Imaging 5 3 1 8 1 2 5 16 Mucus and mucociliary clearance Mucociliary clearance 1 6 4 1 4 Sputum amount and properties 3 1 2 15 Inflammation markers 3 5 8 4 3 19 Molecular and oxidative markers Gene expression and methylation 1 6 Oxidative stress markers 3 1 8 Safety and tolerability 2 60 30 50 48 7 23 Pharmacokinetics 41 8 6 1 11 12 12 Exercise capacity 1 1 3 2 3 39 Muscle strength and endurance 11 Other No measure named 8 5 2 3 1 13
Studies by class and trial phase Rows are the 27 measure classes in the lexicon's order, grouped by domain. Columns are trial phases as the registry records them. Each lit circle is a count of studies, with the number printed beside it. Open the table below for every number. Early phase 1 Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 NA Lung function and gas exchange FEV1 1 6 9 48 1 42 14 43 Other spirometry 1 10 3 6 4 3 19 Lung clearance index 2 3 7 3 11 Airway resistance, compliance and lung volumes 2 11 Oxygen and carbon dioxide levels 4 4 2 1 1 1 9 CFTR function Sweat chloride 1 8 7 Nasal potential difference 1 3 9 1 2 Intestinal current measurement Other CFTR biomarker 4 12 Pulmonary exacerbations 1 2 1 10 8 6 12 Nutrition and growth 2 2 3 2 5 2 30 Bone mineral density 1 5 2 Glucose and cystic fibrosis-related diabetes 2 1 3 3 7 2 31 Sinus and upper airway 1 1 4 3 CFQ-R 2 4 1 16 Imaging 5 3 1 8 1 2 5 16 Mucus and mucociliary clearance Mucociliary clearance 1 6 4 1 4 Sputum amount and properties 3 1 2 15 Inflammation markers 3 5 8 4 3 19 Molecular and oxidative markers Gene expression and methylation 1 6 Oxidative stress markers 3 1 8 Safety and tolerability 2 60 30 50 48 7 23 Pharmacokinetics 41 8 6 1 11 12 12 Exercise capacity 1 1 3 2 3 39 Muscle strength and endurance 11 Other No measure named 8 5 2 3 1 13
Figure 2 as a table: 27 class rows
Figure 2 as a table: studies per class and phase
ClassEarly phase 1Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4NA
FEV1FEV1, Early phase 1: 1FEV1, Phase 1: 6FEV1, Phase 1/2: 9FEV1, Phase 2: 48FEV1, Phase 2/3: 1FEV1, Phase 3: 42FEV1, Phase 4: 14FEV1, NA: 43
Other spirometryOther spirometry, Early phase 1: 1Other spirometry, Phase 1: 10Other spirometry, Phase 1/2: 3Other spirometry, Phase 2: 60Other spirometry, Phase 3: 4Other spirometry, Phase 4: 3Other spirometry, NA: 19
Lung clearance index00Lung clearance index, Phase 1/2: 2Lung clearance index, Phase 2: 30Lung clearance index, Phase 3: 7Lung clearance index, Phase 4: 3Lung clearance index, NA: 11
Airway resistance, compliance and lung volumes000000Airway resistance, compliance and lung volumes, Phase 4: 2Airway resistance, compliance and lung volumes, NA: 11
Oxygen and carbon dioxide levels0Oxygen and carbon dioxide levels, Phase 1: 4Oxygen and carbon dioxide levels, Phase 1/2: 4Oxygen and carbon dioxide levels, Phase 2: 2Oxygen and carbon dioxide levels, Phase 2/3: 1Oxygen and carbon dioxide levels, Phase 3: 1Oxygen and carbon dioxide levels, Phase 4: 1Oxygen and carbon dioxide levels, NA: 9
Sweat chloride0Sweat chloride, Phase 1: 10Sweat chloride, Phase 2: 8000Sweat chloride, NA: 7
Nasal potential difference0Nasal potential difference, Phase 1: 1Nasal potential difference, Phase 1/2: 3Nasal potential difference, Phase 2: 9Nasal potential difference, Phase 2/3: 100Nasal potential difference, NA: 2
Intestinal current measurement00000000
Other CFTR biomarker000Other CFTR biomarker, Phase 2: 4000Other CFTR biomarker, NA: 12
Pulmonary exacerbationsPulmonary exacerbations, Early phase 1: 1Pulmonary exacerbations, Phase 1: 2Pulmonary exacerbations, Phase 1/2: 1Pulmonary exacerbations, Phase 2: 100Pulmonary exacerbations, Phase 3: 8Pulmonary exacerbations, Phase 4: 6Pulmonary exacerbations, NA: 12
Nutrition and growth0Nutrition and growth, Phase 1: 2Nutrition and growth, Phase 1/2: 2Nutrition and growth, Phase 2: 3Nutrition and growth, Phase 2/3: 2Nutrition and growth, Phase 3: 5Nutrition and growth, Phase 4: 2Nutrition and growth, NA: 30
Bone mineral density00000Bone mineral density, Phase 3: 1Bone mineral density, Phase 4: 5Bone mineral density, NA: 2
Glucose and cystic fibrosis-related diabetes0Glucose and cystic fibrosis-related diabetes, Phase 1: 2Glucose and cystic fibrosis-related diabetes, Phase 1/2: 1Glucose and cystic fibrosis-related diabetes, Phase 2: 3Glucose and cystic fibrosis-related diabetes, Phase 2/3: 3Glucose and cystic fibrosis-related diabetes, Phase 3: 7Glucose and cystic fibrosis-related diabetes, Phase 4: 2Glucose and cystic fibrosis-related diabetes, NA: 31
Sinus and upper airway00Sinus and upper airway, Phase 1/2: 1Sinus and upper airway, Phase 2: 10Sinus and upper airway, Phase 3: 40Sinus and upper airway, NA: 3
CFQ-R000CFQ-R, Phase 2: 20CFQ-R, Phase 3: 4CFQ-R, Phase 4: 1CFQ-R, NA: 16
ImagingImaging, Early phase 1: 5Imaging, Phase 1: 3Imaging, Phase 1/2: 1Imaging, Phase 2: 8Imaging, Phase 2/3: 1Imaging, Phase 3: 2Imaging, Phase 4: 5Imaging, NA: 16
Mucociliary clearanceMucociliary clearance, Early phase 1: 1Mucociliary clearance, Phase 1: 60Mucociliary clearance, Phase 2: 400Mucociliary clearance, Phase 4: 1Mucociliary clearance, NA: 4
Sputum amount and properties000Sputum amount and properties, Phase 2: 30Sputum amount and properties, Phase 3: 1Sputum amount and properties, Phase 4: 2Sputum amount and properties, NA: 15
Inflammation markers0Inflammation markers, Phase 1: 3Inflammation markers, Phase 1/2: 5Inflammation markers, Phase 2: 80Inflammation markers, Phase 3: 4Inflammation markers, Phase 4: 3Inflammation markers, NA: 19
Gene expression and methylation000Gene expression and methylation, Phase 2: 1000Gene expression and methylation, NA: 6
Oxidative stress markers000Oxidative stress markers, Phase 2: 300Oxidative stress markers, Phase 4: 1Oxidative stress markers, NA: 8
Safety and tolerabilitySafety and tolerability, Early phase 1: 2Safety and tolerability, Phase 1: 60Safety and tolerability, Phase 1/2: 30Safety and tolerability, Phase 2: 500Safety and tolerability, Phase 3: 48Safety and tolerability, Phase 4: 7Safety and tolerability, NA: 23
Pharmacokinetics0Pharmacokinetics, Phase 1: 41Pharmacokinetics, Phase 1/2: 8Pharmacokinetics, Phase 2: 6Pharmacokinetics, Phase 2/3: 1Pharmacokinetics, Phase 3: 11Pharmacokinetics, Phase 4: 12Pharmacokinetics, NA: 12
Exercise capacity0Exercise capacity, Phase 1: 1Exercise capacity, Phase 1/2: 1Exercise capacity, Phase 2: 3Exercise capacity, Phase 2/3: 20Exercise capacity, Phase 4: 3Exercise capacity, NA: 39
Muscle strength and endurance0000000Muscle strength and endurance, NA: 11
Other00000000
No measure named0No measure named, Phase 1: 80No measure named, Phase 2: 5No measure named, Phase 2/3: 2No measure named, Phase 3: 3No measure named, Phase 4: 1No measure named, NA: 13

What each measure means

Plain-language notes for each measure wait for a clinician's review; until then the atlas shows class names only.

No study in this dated copy: Intestinal current measurement, Other.

Which measures are registered together

A study can register main outcomes in several classes. A separate page counts, for each pair of classes, the studies that registered a main outcome in both: studies, not entries. It shows what trials registered together, not which measures agree, replace or predict each other.

Open the table of measures registered together

If you live with cystic fibrosis or care for someone

This atlas counts what trial teams wrote down as their main outcomes. It says nothing about any treatment, any person's care or whether someone could join a trial. For that, talk with a cystic fibrosis care team.

How this was made

  1. One dated copy. The lab's tools fetched one copy of the registry's answer and recorded a hash of the pages it saved and the date the registry processed the data.
  2. Stated scope. Interventional studies whose condition list names cystic fibrosis, all statuses and dates, were kept. The registry's answer held 1772 studies; 1072 kept. A second search, by term, found 1072 studies in scope. The counts come from the condition search: 0 studies found only by it are counted, and 0 studies found only by the term search are not counted.
  3. Rules sort first. A versioned rule lexicon sorted each main outcome into a class. The rules do not sort vague wording such as “lung function” or “efficacy” as FEV1. Entries with vague wording: 22; naming no measure: 32; not yet in a class: 111. An entry not yet in a class is not the class Other, which a model or a person gives to a measure that fits none of the classes.
  4. A person checks: not recorded in this file. The method calls for a person to label a sample by hand before seeing any rule or model result, and to measure the rules against it. This data file does not record that check.
  5. Counts recomputed. A script recomputes the counts from the dated copy before a page is made, and this page is generated from those counts, not typed. The pairs of classes registered together are counted the same way, from the same dated copy, in studies.

The lab accuracy gate requires precision of at least 0.85 and recall of at least 0.80 where 10 or more entries estimate it (stop rule S1), other plus unclassified under 15.0% (S2), route difference under 10.0% unexplained (S3), and negative controls passed with synthetic markers checked (S0, S4).

Accuracy terms in plain words

Weighted estimate
A weighted estimate accounts for different sampling rates across strata, giving rarer outcome classes higher weight per sampled row so estimates reflect the whole snapshot rather than just the sampled subset.
Few checked
Few checked means fewer than 10 labelled entries were available to reliably estimate precision or recall, so counts are shown without percentage shares or sorting accuracy metrics.
Synthetic marker
A synthetic marker is a testing flag ensuring that artificial test fixtures can never be published as real registry data (stop rule S0).

Download the data

The counts behind the figures, with the same source, dates, changes, license line and note on keeping the data as this page.

How to cite

Sensei Ewok Research Lab (senseiewok.ai). Trial endpoint atlas, dated copy d164700bb17d, lexicon 0.3.2-draft, registry data processed 2026-10-09, accessed [the date you read it]. Counts derived from ClinicalTrials.gov (an online database whose website the U.S. National Library of Medicine maintains).

Fill in the date you read it. A citation names the dated copy, so a reader can tell which counts you saw.

Where the data come from, and what the lab changed

Registry data from ClinicalTrials.gov, an online database; the U.S. National Library of Medicine maintains its website. This lab is independent of the registry; the grouping and counts are the lab's work, not the registry's.

Source
ClinicalTrials.gov
Data processed by the registry
(as given: 2026-10-09T09:00:05; the registry gives no time zone)
Live record
Registry records change; the live record on ClinicalTrials.gov is current, this page is not.
License
The lab's licence covers its own tags, code and counts only; registry text and fields remain ClinicalTrials.gov data under its terms.
No warranty
ClinicalTrials.gov states that the U.S. Government makes no warranties, expressed or implied, about its data and assumes no liability for any party's use of them.
Sponsor responsibility
Study sponsors and investigators write and are responsible for their own records. The registry's Disclaimer says the U.S. government "does not review or approve the safety and science of all studies listed on this website" and that NLM staff only review study information for apparent errors, deficiencies or inconsistencies. See the registry's Disclaimer.
Disclaimer page
https://clinicaltrials.gov/about-site/disclaimer
Disclaimer last updated
2023-08-03
The registry's terms page, the dated copy's date, every change the lab made, and keeping the data
Dated copy taken
(2026-10-11 03:59:17 UTC)
Registry terms
Terms and Conditions of ClinicalTrials.gov (opens another site) (last updated )
Changes the lab made
  1. Primary-outcome wording was classified into classes by the versioned rule lexicon 0.3.2-draft (sha256 f4bd1af4c664); a model-proposed class is counted only when its quote is an exact piece of the registry text.
  2. Studies were left out by stated scope rules, with these counts: X1 554, X2 7, X3 0, X4 91, X5 48, X6 0 (explained in trial-atlas-data-dictionary.txt; X6 is a person's exclusion list).
  3. Start dates without a recorded date type are counted as their own kind; no type is assumed.
  4. No registry wording was clipped by these tools; any clipping on a published page must be added to this list.
  5. Registry pages were re-saved as UTF-8 JSON after parsing; values and key order are kept, whitespace is not.
  6. This page and its downloads show counts only: no registry wording, trial ids or sponsor names.
  7. Start years are also grouped into five-year periods for narrow screens; the yearly counts are in the downloads.
  8. Phase codes are written in plain words (PHASE1 as Phase 1, PHASE1/PHASE2 as Phase 1/2, EARLY_PHASE1 as Early phase 1); NA is shown as written, and a study with no phase is shown as None given.
Keeping the data
The registry's terms apply for as long as the data are kept, in any copy, file or page made from them.
Third party copyright
Some registry data may be subject to third-party copyright, and the data carry an international copyright outside the United States and its Territories or Possessions.
Keep current
The registry says it is updated daily and that data in any publication or distribution should be kept current at all times. This copy is dated and may be out of date; the live record is the current one.

Not affiliated with the Cystic Fibrosis Foundation or with ClinicalTrials.gov. This is an independent lab. Its work is research, not medical advice.

Registry data from ClinicalTrials.gov, an online database; the U.S. National Library of Medicine maintains its website. This lab is independent of the registry; the grouping and counts are the lab's work, not the registry's.